and on the other side binds to NK cells to stimulate a phenomenon known as antibody-dependent cellular cytotoxicity (ADCC), which prompts immune cells to kill cancer cells. Experiments on NSCLC ...

Figure 1: Antibody design to improve homogeneity and ... and associated with enhanced or silenced effector functions (ADCC or complement-dependent cytotoxicity) are being investigated in clinical ...

In RTX-003, a CD25 T reg cell-targeting program, RubrYc used MEMs to identify epitopes and antibodies that enhance antibody directed cellular cytotoxicity (ADCC). This results in T reg cell ...

Table 1. The types and characteristics of FcγRs. Source: Sino Biological Inc. To mediate antibody-dependent cellular cytotoxicity (ADCC), NK cells recognize cell-bound antibodies via CD16A ...

ADCC: Antibody-dependent cellular cytotoxicity; CDC: Complement-dependent cytotoxicity. Ofatumumab shows good efficacy in conditions with low CD20 expression and is approved for relapsed ...

and on the other side binds to NK cells to stimulate a phenomenon known as antibody-dependent cellular cytotoxicity (ADCC), which prompts immune cells to kill cancer cells. Experiments on NSCLC ...

By design, there is significantly less antibody-dependent cellular cytotoxicity (ADCC) with STAR-0310 compared to rocatinlimab, an OX40 antagonist currently in Phase 3 development for the ...

antibody-dependent cellular phagocytosis (ADCP), antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent complement deposition (ADCD), and CDC. All three anti-CD20 mAbs, RTX ...

or bring a T cell adjacent to the tumor (e.g., bispecific mAb). ADCC: Antibody-dependent cellular cytotoxicity; mAb: Monoclonal antibody.

NK cells recognize cell-bound antibodies via CD16A (FcγRIIIA) to mediate antibody-dependent cellular cytotoxicity (ADCC). Potentiating therapeutic mAb-mediated CD16 activation of NK cells is an ...